{"name":"Aveta Biomics, Inc.","slug":"aveta-biomics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"APG-157","genericName":"APG-157","slug":"apg-157","indication":"Acute myeloid leukemia (AML)","status":"phase_2"}]}],"pipeline":[{"name":"APG-157","genericName":"APG-157","slug":"apg-157","phase":"phase_2","mechanism":"APG-157 is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog.","indications":["Acute myeloid leukemia (AML)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPN2lzOUM2dHhKRE5LR2ZQMHhzTmxaNk1YZnBpV0tQTUJlVGU0S3hoN2hmTVFmUFByeXlIMmYzRVpYejFjdUp4eWFYOTZ0M3BRa2xLUnNPeHQzUVIyTEJYeDNieExFQVRGZ1dBS1hwUGJYSTNYOG9JUWYxc1BFM2hpbkpXNVZQV2VGU0wwLVdnSjJHbXV3OVkxYTBNZ2hDSUk3dmRTUmVrb25wWkpISmkzblhNaGt6aHloN05nREFMVi1iOGlNV29zVzVnTm81N2oya1pBTElxeTMtbTNReWZrYjBUU05WUmNjQ1RQaTdtWFNzZzBCN2c?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com","headline":"Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsig","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AJBVV95cUxQOGdNMTN1RElfTmhkU0xLTTZlV3Z4OTNEUjFyYjJLNzVjaFdUbDVHSjFrUXREZjAyLXF5clh4Q2x4U29Eb2loQkttODdYOVlUd2hFZkxPOEJDV0xIdEQ1OGZEaUQxMHVCR09NLS1Cd19QS0JxX3M5Q1I2RGtHQUpxTlZ2ZGpvUTNJdVo5ejQ5MGktaC1fdE85MnliWVc5eHpwdnZyMXhQU1d5N01MX3ItZktMLTd0bW5fcTVxNDVOeU44YnFSd3FjVWt6LXhhcXRadnAtRGlNYTR4MmlQbkNaY01fZTJLek1vWXdfRzZxV1FKSVNXV0RwbThRR21NNUlwbFExSG9CVnhuLVhiZFlkWHYwYXdJQzR3SGZSQzl6MS1HRjVZOTNKTTVzdm1RTmRwRVc0MWdrMTVMa2RQRTFaSlZncFNKVGJBYS1ibzdBNHI?oc=5","date":"2026-03-19","type":"pipeline","source":"Barchart.com","summary":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Bar","headline":"Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxONVZJeDU0M1VaVEMzTUhLMy1JMzZDQ0NIUGlQX0g2dG83ZkJZWU5YWTVaRUlUWnpjVDlNTEZXaHJ1MFp1WGtCeGNORDhHMWU5bXNJbzc5eURscW9CTy1CVTdpRnhpYURyQk85WC1Hd3NtSkZuZjJ1ZVVHYmdjTUUzSmo5VE1YZWE2R0hkcVd3aGxkTERtZXAyZnNvOER3dzRTM1JtQWpqNmhxYWx2bkxkeE5jYmRabUZmdWZDLTlqUndOQ1JuUHRSZGxWLXROMEZmTTB2cmYzNGFkVEs0b3NQVjdBSWNPMGRycWZlQ1p0RXlFNURCTWQxLTZxYjVnYW9DMG95REc4T095aGdS?oc=5","date":"2025-02-05","type":"pipeline","source":"BioSpace","summary":"Lip and Oral Cavity Cancer Market Expected to Grow at a CAGR of 3.82% during 2025-2035, Impelled by Advancements in AI-driven Diagnostic Tools - BioSpace","headline":"Lip and Oral Cavity Cancer Market Expected to Grow at a CAGR of 3.82% during 2025-2035, Impelled by Advancements in AI-d","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPLXV2Q3hTZjF2Y0doVjRObExaam5fZXYyZmdlbzZMc1c0UlA5bm5RYVNCT0R0dGpxMjhxc2NiUUhvOTlYSnQ5UEFpUUhscmVwWUFTNUcyd2R2cXFuMWRNMVVmR0ZSSkYzaDhQektzRTFnb3Y3TFJ4MC1lRW1Yc1hyZHNtVGRxRzN4VXFHNzh0bmdFTzJyT3o0ZUtnNm16LThyaEJBQ3VoTzZyN1JjY18yN1JjdmZibDNKSmN0eklXbEJ6WW5PbjhnM3A4NUFBYTUwRHRSeDZXQWRkNDdCVkNJbjBSeTZXVUFMemcxWTBydng2SlFDbXhMUm1KMmlFMTBwUDZudjM5X2FGX0Fpd3BOR2xlMFNzcS1FNXZKcXpVdlg?oc=5","date":"2022-02-02","type":"deal","source":"PR Newswire","summary":"Aveta Biomics and CSIR-CDRI Announce License to Aveta Biomics for the Development and Commercialization of First-in-Class Bone Health Drugs - PR Newswire","headline":"Aveta Biomics and CSIR-CDRI Announce License to Aveta Biomics for the Development and Commercialization of First-in-Clas","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}